Essex Bio-Technology Ltd
01061
Company Profile
Business description
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People’s Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Contact
No. 88, Keji 6th Road
Hi-Tech Zone
Guangdong
Zhuhai
CHNT: +86 7563911188
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,426
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,245.00 | 149.32 | -1.78% |
| DAX 40 | 24,093.16 | 544.84 | -2.21% |
| Dow JONES (US) | 48,838.69 | 139.23 | -0.28% |
| FTSE 100 | 10,619.35 | 160.76 | -1.49% |
| HKSE | 25,768.08 | 291.77 | -1.12% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 1,778.19 | -3.06% |
| NZX 50 Index | 13,620.21 | 102.76 | -0.75% |
| S&P 500 | 6,875.63 | 3.25 | -0.05% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |